Company intelligence / Profile preview

DMI BioSciences, Inc.

Aurora, Colorado, United States

Ownership: Private
Development stage: Other

Overview

DMI BioSciences developed drugs for male sexual dysfunction including a Phase III-ready drug for premature ejaculation (unique lower dose of approved drug with Phase II efficacy data) and combination drugs for premature ejaculation and erectile dysfunction; additional pipeline includes pending-stage programs in atopic dermatitis, neoplasms, myocardial infarction, perioperative ischaemia, and asthma.

Therapeutic areas: CardiovascularDermatologyPulmonologyOncologyMen's Health
Modalities: Small molecule
Industry: Biotech

Partnerships

international specialty pharmaceutical company (former licensee for PE drug)

Beyond the preview

Go deeper on DMI BioSciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMI BioSciences, Inc..

Explore the full profile